Single User

Atrial Fibrillation 2015-2020

Heart & Cardiovascular

Epiomic Insights for Atrial Fibrillation (AF) provides you with a top line snapshot of the market potential for the most prevalent type of supraventricular arrhythmia. With growing AF incidences, alongside an aging population, the ability to quantify the eligible patient populations for innovative new treatments or diagnostics will be essential to achieve commercial success.

Sourcing data from our Epiomic Patient segmentation database, we are able to reference relevant clinical trial data and patient registries to provide a picture of the total projected prevalent population across 8 major global markets.

This one-page synopsis developed by our team of analysts delivers a current overview of the disease and risk factors with a perspective on the future drivers of the patient population. The total AF population across all markets has also been segmented by gender type and by duration of episode.

This style of report is ideal for companies entering a new market segment or disease area of which they have limited knowledge. Alternatively, companies considering investing in healthcare innovation may benefit from a high-level, accurate overview of the market to determine likely commercial potential of such an investment.